- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06281327
Avatrombopag in the Treatment of Pediatric Immune Thrombocytopenia
A Prospective, One-arm and Open Clinical Study to Assess Efficacy and Safety of Avatrombopag in the Treatment of Pediatric Primary Immune Thrombocytopenia
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Immune thrombocytopenia (ITP) is an organ-specific autoimmune disease, which is characterized by decreased platelet count and skin and mucosal bleeding. ITP is a kind of disease with increased platelet destruction and impaired platelet production caused by autoimmunity. Conventional treatment of adult ITP includes first-line glucocorticoid and immunoglobulin therapy, second line TPO and TPO receptor agonist, splenectomy and other immunosuppressive treatments (such as rituximab, vincristine, azathioprine, etc.).
Eltrombopag is currently the only TPO receptor agonist with indications for pediatric immune thrombocytopenia. However, at present, the treatment response of pediatric ITP is not good, and a considerable number of patients need to switched to other TPO receptor agonist, such as avatrombopag, because of poor efficacy, excessive platelet fluctuation or intolerance, or patient preference, economic reasons, and other reasons.
Therefore, the investigators designed this clinical trial to evaluate the efficacy and safety of avatrombopag in the treatment of pediatric immune thrombocytopenia in patients who who have been treated with eltrombopag before and switched to avatrobopag because of different reasons.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Ting Sun, MD
- Phone Number: +8615822339131
- Email: sunting@ihcams.ac.cn
Study Contact Backup
- Name: Lei Zhang, MD
- Phone Number: +86 13502118379
- Email: zhanglei1@ihcams.ac.cn
Study Locations
-
-
-
Tianjin, China
- Recruiting
- Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
-
Contact:
- Lei Zhang, MD
- Phone Number: +8602223909009
- Email: zhanglei1@ihcams.ac.cn
-
Contact:
- Ting Sun, MD
- Phone Number: +8602223909009
- Email: sunting@ihcams.ac.cn
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age 6-18 years old (including both ends), male and female;
- Diagnosed with primary immune thrombocytopenia (ITP);
- Patients who had previously received eltrombopag treatment and then converted to avatrombopag treatment because of ineffectiveness (platelet count < 30×10^9/L after eltrombopag treatment, or platelet count increased less than 2 times of the basic value, or bleeding) or large platelet fluctuation or due to patient preference, economic reasons and other reasons;
- Cardiac function of the New York Society of Cardiac Function ≤ 2;
- Understand the study procedure and voluntarily sign the informed consent.
Exclusion Criteria:
- Secondary thrombocytopenia caused by various reasons, such as connective tissue disorders, bone marrow hematopoietic failure disease, myelodysplastic syndrome, malignancy, drugs, inherited thrombocytopenia, common variable immune deficiency, lymphoma, etc.;
- Subjects with primary disease of important organs (liver, kidney, heart, etc.), or with immune system diseases;
- Subjects who are known to be allergic to avatrombopag or any of its excipients;
- Subjects who had used rituximab within the last 3 months;
- Subjects who underwent splenectomy within the last 3 months;
- Subjects with a history of abnormal platelet aggregation that may affect the reliability of platelet count measurements;
- Any medical history or condition that the investigator deems unsuitable for participation in the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment group: Avatrombopag
Sixty subjects will be enrolled with the indicated treatment dose of avatrombopag
|
After enrollment, all subjects receive Avatrombopag treatment. The initial dose of Avatrombopag administration was an oral 10 mg (<30kg) or 20mg (≥30kg) once daily in all participants. ps. For subjects weighing ≥30kg, the dose can be started from 40mg once daily if the platelet count is < 10×10^9/L or if there is severe bleeding or risk of bleeding. Complete blood count including platelet count was done once a week. The dose of Avatrombopag was adjusted according to the subject platelet count during the period from week 1 to week 24. If the platelet count was less than 30×10^9/L for 2 weeks, avatrobopag was gradually increased. If the platelet count was greater than 150 x 10^9/L, avatrobopag was gradually reduced. If the platelet count >250×10^9/L, avatrobopag will be stoped until the platelet count <100×10^9/L. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall efficacy response after AVA treatment within 12 weeks
Time Frame: 12 weeks
|
Overall response rate defined as proportion of subjects with a platelet count ≥ 30 × 10^9/L and at least 2-fold from baseline without bleeding at the meanwhile within 12 weeks after initial administration in absence of rescue therapy.
|
12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Treatment response-1
Time Frame: 12 weeks
|
Number of participants achieving a platelet count ≥ 50×10^9/L at week 1,2,4,6,8,12 in absence of rescue therapy.
|
12 weeks
|
Treatment response-2
Time Frame: 12 weeks
|
Number of participants achieving a platelet count ≥ 100×10^9/L at week 1,2,4,6,8,12 in absence of rescue therapy.
|
12 weeks
|
Time to Response
Time Frame: 12 weeks
|
The time required from the start of treatment to the first time a subject's platelet count was greater than or equal to 30×10^9/L and at least a two-fold increase from the baseline platelet count without bleeding in absence of rescue therapy.
|
12 weeks
|
Persistent response
Time Frame: 12 weeks
|
Persistent response defined as proportion of subjects with a platelet count ≥ 30 × 10^9/L and at least 2-fold from baseline without bleeding for 4 consecutive weeks or more within 12 weeks after initial administration in absence of rescue therapy.
|
12 weeks
|
Emergency treatment
Time Frame: 12 weeks
|
The proportion of subjects receiving emergency treatment
|
12 weeks
|
Reduction of concomitant drug
Time Frame: 12 weeks
|
Percentage of patients with reduced doses of concomitant drugs at baseline
|
12 weeks
|
Number of participants with clinically significant bleeding as assessed using the world health organization (WHO) bleeding scale.
Time Frame: 12 weeks
|
The WHO Bleeding Scale is a measure of bleeding severity with the following grades: grade 0 = no bleeding, grade 1= petechiae, grade 2= mild blood loss, grade 3 = gross blood loss, and grade 4 = debilitating blood loss.
|
12 weeks
|
Number of participants with clinically significant bleeding as assessed using the bleeding scale for pediatric patients with ITP.
Time Frame: 12 weeks
|
The bleeding scale for pediatric patients with ITP is a measure of bleeding severity with the following grades: Grade 1 (minor) Minor bleeding, few petechiae (≤100 total) and/or ≤5 small bruises (≤3 cm in diameter), no mucosal bleeding;Grade 2 (mild) Mild bleeding, many petechiae (>100 total) and/or >5 large bruises (>3 cm in diameter), no mucosal bleeding;Grade 3 (moderate) Moderate bleeding, overt mucosal bleeding, troublesome lifestyle;Grade 4 (severe) Severe bleeding, mucosal bleeding leading to decrease in Hb>2 g/dL or suspected internal hemorrhage;
|
12 weeks
|
Health-related quality of life survey of subjects(HRQoL)-1
Time Frame: 12 weeks
|
In all participants ,use ITP-PAQ (ITP Patient Assessment Questionnaire) to assess the HRQoL before and after treatment.
|
12 weeks
|
Health-related quality of life survey of subjects(HRQoL)-2
Time Frame: 12 weeks
|
In all participants ,use FACIT-F(functional assessment of chronic illness therapy- fatigue)to assess the HRQoL before and after treatment.
|
12 weeks
|
Health-related quality of life survey of subjects(HRQoL)-3
Time Frame: 12 weeks
|
In all participants ,use Kids' ITP tool KIT、to assess the HRQoL before and after treatment.
|
12 weeks
|
Health-related quality of life survey of subjects(HRQoL)-4
Time Frame: 12 weeks
|
In all participants ,use Pediatric Quality of Life Inventory PedsQL to assess the HRQoL before and after treatment.
|
12 weeks
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Lei Zhang, MD, Institute of Hematology & Blood Diseases Hospital, China
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Immune System Diseases
- Autoimmune Diseases
- Hematologic Diseases
- Hemorrhage
- Hemorrhagic Disorders
- Blood Coagulation Disorders
- Skin Manifestations
- Blood Platelet Disorders
- Thrombotic Microangiopathies
- Purpura, Thrombocytopenic
- Purpura
- Purpura, Thrombocytopenic, Idiopathic
- Thrombocytopenia
Other Study ID Numbers
- TX-ITP-001
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Immune Thrombocytopenia
-
Institute of Hematology & Blood Diseases Hospital...Henan Cancer Hospital; Beijing Children's Hospital; Tianjin Medical University... and other collaboratorsRecruitingPrimary Immune Thrombocytopenia (ITP)China
-
argenxWithdrawnPrimary Immune Thrombocytopenia (ITP)
-
Novartis PharmaceuticalsRecruitingPrimary Immune Thrombocytopenia (ITP)China, United States, Spain, Singapore, Austria, Germany, Belgium, Italy, Japan, Czechia, Hong Kong, Hungary, Malaysia, Argentina, Bulgaria, Turkey, Vietnam, Australia, Thailand, Mexico, United Kingdom, France, Romania, Norway, India
-
University Children's Hospital BaselNovartis Pharmaceuticals; Stiftung zur Förderung medizinischer und biologischer... and other collaboratorsActive, not recruiting
-
Gruppo Italiano Malattie EMatologiche dell'AdultoCompletedAdult Patients | Immune Primary Thrombocytopenia | Splenectomy | TPO-mimeticsItaly
-
National Heart, Lung, and Blood Institute (NHLBI)Enrolling by invitationImmune Mediated Anemia | Immune Mediated Thrombocytopenia | Chronic GVHDUnited States
-
National Heart, Lung, and Blood Institute (NHLBI)RecruitingImmune Mediated Anemia | Immune Mediated Thrombocytopenia | Chronic GVHDUnited States
-
Changzhou No.2 People's HospitalRui Therapeutics Co., LtdNot yet recruitingThrombocytopenia Alloimmune
-
Nahda UniversityRecruiting
-
Beijing InnoCare Pharma Tech Co., Ltd.RecruitingChronic Primary Immune Thrombocytopenia (ITP)China
Clinical Trials on Avatrombopag
-
Institute of Hematology & Blood Diseases Hospital...Fosun Pharmaceutical Distribution Jiangsu co., LimitedNot yet recruiting
-
Peking Union Medical College HospitalRecruitingThrombocytopenia | AvatrombopagChina
-
Anhui Provincial HospitalRecruitingPlatelet Recovery After Umbilical Cord Blood TransplantationChina
-
Eisai Inc.Completed
-
Swedish Orphan BiovitrumActive, not recruitingImmune Thrombocytopenia | ITPCroatia, Czechia, Germany, Italy, Netherlands, Norway, Spain, Switzerland, United Kingdom
-
Shanghai Zhongshan HospitalRecruiting
-
Anhui Provincial Cancer HospitalCompleted
-
Sobi, Inc.Active, not recruitingEvaluation of Avatrombopag for the Treatment of Thrombocytopenia in Japanese Adults With Chronic ITPImmune ThrombocytopeniaJapan
-
Sobi, Inc.TerminatedThrombocytopeniaUnited States
-
Institute of Hematology & Blood Diseases HospitalPeking University People's Hospital; Xiyuan Hospital of China Academy of Chinese... and other collaboratorsRecruitingRefractory Aplastic AnemiaChina